Protocol for establishing an Adaptive Diseases control Expert Programme in Tanzania (ADEPT) for integrating care of communicable and non-communicable diseases using tuberculosis and diabetes as a case study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
28 04 2021
Historique:
entrez: 29 4 2021
pubmed: 30 4 2021
medline: 20 5 2021
Statut: epublish

Résumé

Most sub-Saharan African countries endure a high burden of communicable infections but also face a rise of non-communicable diseases (NCDs). Interventions targeting particular epidemics are often executed within vertical programmes. We establish an Adaptive Diseases control Expert Programme in Tanzania (ADEPT) model with three domains; stepwise training approach, integration of communicable and NCDs and a learning system. The model aims to shift traditional vertical programmes to an adaptive diseases management approach through integrating communicable and NCDs using the tuberculosis (TB) and diabetes mellitus (DM) dual epidemic as a case study. We aim to describe the ADEPT protocol with underpinned implementation and operational research on TB/DM. The model implement a collaborative TB and DM services protocol as endorsed by WHO in Tanzania. Evaluation of the process and outcomes will follow the logic framework. A mixed research design with both qualitative and quantitative approaches will be used in applied research action. Anticipated implementation research outcomes include at the health facilities level for organising TB/DM services, pathways of patients with TB/DM seeking care in different health facilities, factors in service delivery that need deimplementation and the ADEPT model implementation feasibility, acceptability and fidelity. Expected operational research outcomes include additional identified patients with dual TB/DM, the prevalence of comorbidities like hypertension in patients with TB/DM and final treatment outcomes of TB/DM including treatment-related complications. Findings will inform the future policies and practices for integrating communicable and NCDs services. Ethical approval was granted by The National Research Health Ethical Committee (Ref-No. NIMR/HQ/R.8a/Vol.IX/2988) and the implementation endorsed by the government authorities. Findings will be proactively disseminated through multiple mechanisms including peer-reviewed journals, and engagement with various stakeholders' example in conferences and social media.

Identifiants

pubmed: 33910944
pii: bmjopen-2020-041521
doi: 10.1136/bmjopen-2020-041521
pmc: PMC8094344
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e041521

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Eur Respir J. 2016 Feb;47(2):680-2
pubmed: 26828056
Int J Tuberc Lung Dis. 2018 Dec 1;22(12):1404-1410
pubmed: 30606312
Trans R Soc Trop Med Hyg. 2016 Mar;110(3):173-9
pubmed: 26884497
J Infect Dev Ctries. 2016 Apr 28;10(4):423-6
pubmed: 27131008
Int J Tuberc Lung Dis. 2016 Aug;20(8):1014-21
pubmed: 27393533
Public Health Nutr. 2014 Mar;17(3):634-9
pubmed: 23507463
J Infect. 2017 Jan;74(1):10-21
pubmed: 27717783
Eur Respir J. 2016 Oct;48(4):1230-1233
pubmed: 27587558
Health Policy Plan. 2012 Oct;27 Suppl 4:iv54-61
pubmed: 23014154
Hum Reprod. 2016 Mar;31(3):498-501
pubmed: 26759142
Lancet Diabetes Endocrinol. 2014 Sep;2(9):740-53
pubmed: 25194887
BMC Public Health. 2020 Nov 7;20(1):1667
pubmed: 33160327
BMC Infect Dis. 2017 Jun 2;17(1):388
pubmed: 28577535
Infect Dis Poverty. 2016 Mar 21;5:22
pubmed: 27009088
PLoS One. 2020 Jul 9;15(7):e0235542
pubmed: 32645054
Res Soc Work Pract. 2009 Sep 1;19(5):503-518
pubmed: 20976022
Lancet Diabetes Endocrinol. 2016 Jan;4(1):8-10
pubmed: 26620249
Trop Med Int Health. 2013 Jul;18(7):822-9
pubmed: 23648145
Ther Drug Monit. 2019 Aug;41(4):409-430
pubmed: 31268966
Clin Infect Dis. 2020 Apr 10;70(8):1774-1780
pubmed: 31560376
BMC Public Health. 2019 Aug 14;19(1):1104
pubmed: 31412829
BMC Public Health. 2019 Apr 11;19(1):395
pubmed: 30971228
BMJ. 2015 Feb 06;350:h391
pubmed: 25662947
Sci Rep. 2017 May 17;7(1):1999
pubmed: 28515464
Health Policy Plan. 2004 Sep;19(5):336-45
pubmed: 15310668
Trop Med Int Health. 2010 Jun;15(6):659-63
pubmed: 20406430
PLoS One. 2013 May 13;8(5):e62034
pubmed: 23675411
BMC Public Health. 2014 Sep 02;14:904
pubmed: 25183300
Am J Trop Med Hyg. 2017 Oct;97(4):1099-1102
pubmed: 28820679
Int J Mycobacteriol. 2019 Oct-Dec;8(4):313-319
pubmed: 31793499
Health Phys. 2008 Jul;95(1):36-46
pubmed: 18545028
BMJ Open. 2020 Nov 11;10(11):e040908
pubmed: 33177143
Emerg Infect Dis. 2010 Oct;16(10):1546-53
pubmed: 20875279
Clin Microbiol Infect. 2020 Aug;26(8):1008-1016
pubmed: 32205294

Auteurs

Stellah G Mpagama (SG)

Medical, Kibong'oto Infectious Diseases Hospital, Sanya Juu, Tanzania sempagama@yahoo.com.

Kaushik Ramaiya (K)

Department of Internal Medicine, Shree Hindu Mandal Hospital, Dar es Salaam, Tanzania.

Troels Lillebæk (T)

Statens Serum Institut, Kobenhavn, Denmark.

Blandina T Mmbaga (BT)

Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania.

Marion Sumari-de Boer (M)

Kilimanjaro Clinical Research Institute, Moshi, Tanzania.

Nyanda Elias Ntinginya (NE)

National Institute of Medical Research-Mbeya Medical Research Centre, Mbeya, Tanzania.

Jan-Willem Alffenaar (JW)

Rijksuniversiteit Groningen, Groningen, The Netherlands.

Scott K Heysell (SK)

Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA.

Ib C Bygbjerg (IC)

Global Health Section, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.

Dirk L Christensen (DL)

Global Health Section, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH